Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CLPP | Q16740 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301167 | 0.94 | PRLHR (0.48) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL17358374 | 0.93 | RECQL (0.48) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3301087 | 0.92 | RECQL (0.47) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3299970 | 0.92 | PRLHR (0.45) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3300072 | 0.90 | PRLHR (0.53) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3299790 | 0.90 | RECQL (0.46) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3296514 | 0.89 | PRLHR (0.47) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3298474 | 0.89 | PRLHR (0.45) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3297966 | 0.89 | PRLHR (0.45) | PRLHRRECQLALDH1A1MAPTNPC1 | |
| SCHEMBL3297770 | 0.89 | PRLHR (0.50) | PRLHRRECQLALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232282-B2 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2078719-A1 | COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | GART, MGAT2, MGAT1 | PRLHR 3093/4885RECQL 1541/4885ALDH1A1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.